Антилейкотриеновые средства в сравнении с ингаляционными кортикостероидами в управлении рецидивной и/или хронической астмой у взрослых и детей
Abstract
Background
Anti‐leukotrienes (5‐lipoxygenase inhibitors and leukotriene receptors antagonists) serve as alternative monotherapy to inhaled corticosteroids (ICS) in the management of recurrent and/or chronic asthma in adults and children.
Objectives
To determine the safety and efficacy of anti‐leukotrienes compared to inhaled corticosteroids as monotherapy in adults and children with asthma and to provide better insight into the influence of patient and treatment characteristics on the magnitude of effects.
Search methods
We searched MEDLINE (1966 to Dec 2010), EMBASE (1980 to Dec 2010), CINAHL (1982 to Dec 2010), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (Dec 2010), abstract books, and reference lists of review articles and trials. We contacted colleagues and the international headquarters of anti‐leukotrienes producers.
Selection criteria
We included randomised trials that compared anti‐leukotrienes with inhaled corticosteroids as monotherapy for a minimum period of four weeks in patients with asthma aged two years and older.
Data collection and analysis
Two review authors independently assessed the methodological quality of trials and extracted data. The primary outcome was the number of patients with at least one exacerbation requiring systemic corticosteroids. Secondary outcomes included patients with at least one exacerbation requiring hospital admission, lung function tests, indices of chronic asthma control, adverse effects, withdrawal rates and biological inflammatory markers.
Main results
Sixty‐five trials met the inclusion criteria for this review. Fifty‐six trials (19 paediatric trials) contributed data (representing total of 10,005 adults and 3,333 children); 21 trials were of high methodological quality; 44 were published in full‐text. All trials pertained to patients with mild or moderate persistent asthma. Trial durations varied from four to 52 weeks. The median dose of inhaled corticosteroids was quite homogeneous at 200 µg/day of microfine hydrofluoroalkane‐propelled beclomethasone or equivalent (HFA‐BDP eq). Patients treated with anti‐leukotrienes were more likely to suffer an exacerbation requiring systemic corticosteroids (N = 6077 participants; risk ratio (RR) 1.51, 95% confidence interval (CI) 1.17, 1.96). For every 28 (95% CI 15 to 82) patients treated with anti‐leukotrienes instead of inhaled corticosteroids, there was one additional patient with an exacerbation requiring rescue systemic corticosteroids. The magnitude of effect was significantly greater in patients with moderate compared with those with mild airway obstruction (RR 2.03, 95% CI 1.41, 2.91 versus RR 1.25, 95% CI 0.97, 1.61), but was not significantly influenced by age group (children representing 23% of the weight versus adults), anti‐leukotriene used, duration of intervention, methodological quality, and funding source. Significant group differences favouring inhaled corticosteroids were noted in most secondary outcomes including patients with at least one exacerbation requiring hospital admission (N = 2715 participants; RR 3.33; 95% CI 1.02 to 10.94), the change from baseline FEV1 (N = 7128 participants; mean group difference (MD) 110 mL, 95% CI 140 to 80) as well as other lung function parameters, asthma symptoms, nocturnal awakenings, rescue medication use, symptom‐free days, the quality of life, parents' and physicians' satisfaction. Anti‐leukotriene therapy was associated with increased risk of withdrawals due to poor asthma control (N = 7669 participants; RR 2.56; 95% CI 2.01 to 3.27). For every thirty one (95% CI 22 to 47) patients treated with anti‐leukotrienes instead of inhaled corticosteroids, there was one additional withdrawal due to poor control. Risk of side effects was not significantly different between both groups.
Authors' conclusions
As monotherapy, inhaled corticosteroids display superior efficacy to anti‐leukotrienes in adults and children with persistent asthma; the superiority is particularly marked in patients with moderate airway obstruction. On the basis of efficacy, the results support the current guidelines' recommendation that inhaled corticosteroids remain the preferred monotherapy.
PICO
Plain language summary
Антилейкотриеновые средства в сравнении с ингаляционными кортикостероидами для людей, страдающих астмой
При приступе астмы дыхательные пути (пути к легким) сужаются из‐за мышечных спазмов (бронхоспазм), воспаления (отека, опухания) и секреции слизистой мокроты. Результатом сужения дыхательных путей и уменьшения их проходимости являются проблемы с дыханием, свистящее дыхание и кашель. Ингаляционные кортикостероиды считаются золотым стандартом для уменьшения воспаления дыхательных путей у взрослых и детей с бронхиальной астмой. Антилейкотриены (ингибиторы 5‐липоксигеназы и антагонисты лейкотриеновых рецепторов) являются противовоспалительными лекарственными средствами, которые могут иметь меньше побочных эффектов, чем ингаляционные кортикостероиды. Обзор предполагает, что антилейкотриены безопасны, но менее эффективены, чем низкие дозы ингаляционных кортикостероидов.
